Development and Validation of Analytical Methods for Radiochemical Purity of ¹⁷⁷Lu-PSMA-1.

ABSTRACT: Prostate Specific Membrane Antigen (PSMA) is a highly relevant target in nuclear medicine due to its overexpression in prostate cancer. The ⁶⁸Ga/¹⁷⁷Lu-PSMA-1 combination is a theranostic agent for the detection and treatment of tumors overexpressing the PSMA target. Specifically, ¹⁷⁷Lu-PSMA-1 is used in the treatment of castration-resistant prostate cancer that is ineffective or intolerant to the latest generation of chemotherapy and/or hormone therapy. This radiopharmaceutical is manufactured in a radiopharmaceutical synthesizing unit and must pass a quality control where the radiochemical purity (RCP) is assessed prior to release of the batch. RCP evaluation is performed by high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC).

SUBMITTER: Orhon P 

PROVIDER: S-EPMC9143309 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature